Biocryst Pharmaceuticals opened lower at $7.58, compared with its previous close of $7.65. In the last trading session, the stock traded between $7.46 and $7.78. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Biocryst Pharmaceuticals is now worth
$ 62.10
Resulting in a loss of
$ 37.90 (37.90%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
66.67%
Hold
33.33%
Sell
0%
Markets Today
Today's Change
+$0.03 (+0.33%)
Day High
$7.78
Day Low
$7.46
Day Open
$7.58
Prev Close
$7.65
Volume
28,20,338
1W Return
-7.05%
1M Return
-8.14%
3M Return
-25.77%
6M Return
-10.55%
1Y Return
6.15%
Fundamentals
Market Cap ($ Mn)
1,975
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
110.06%
EPS (TTM)
$0.15
Investment Returns
1 Week
-7.05%
1 Month
-8.14%
3 Months
-25.77%
6 Months
-10.55%
9 Months
12.21%
Financials
Quarterly
All values in $ Mn
163.4
Jun 25
159.4
Sep 25
406.6
Dec 25
156.4
Mar 26
218.3
Jun 26
180.3
Sep 26
Updates
5Nov
Wedbush lowers BioCryst Pharmaceuticals price target to $17
Wedbush analyst Laura Chico lowered the price target for BioCryst Pharmaceuticals to $17. The previous price target was set at $18. The firm maintained an Outperform rating on the stock.
7 days ago
22Oct
BioCryst Pharmaceuticals Q3FY26 Results: Earnings call set for Nov 4
BioCryst Pharmaceuticals will report third quarter 2026 financial results on November 4, 2026. Conference call and webcast scheduled for 8:30 am ET on the same day. Live webcast and replay available via the investors section of the company website.
22 days ago
21Oct
FDA approves BioCryst's oral pellet ORLADEYO for HAE prophylaxis
FDA approves sNDA for 150 mg oral pellet formulation of ORLADEYO. New option available for adults and adolescents aged 12 and older with HAE. Pellets can be swallowed directly or sprinkled on soft, non-acidic food. Expands BioCryst's targeted oral prophylactic therapy portfolio.
22 days ago
1Sep
BioCryst plans presentation at Morgan Stanley healthcare conference
BioCryst Pharmaceuticals plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference. The presentation is scheduled for Tuesday, September 15, 2026, at 9:15 am ET in New York. Live audio webcast and replay will be available on the company’s investor relations website.
2mo ago
25Aug
BioCryst secures Japan approval for pediatric HAE drug ORLADEYO
Japan's MHLW approves ORLADEYO for HAE patients aged 2 to <12 years. Expands access to first oral prophylactic option for this pediatric group. Launch pending completion of NHI reimbursement pricing process. Approval based on APeX-P trial data showing sustained attack rate reduction.
2mo ago
7Aug
Wedbush keeps Outperform on BioCryst Pharma, cuts price target to $20
Wedbush analyst Laura Chico maintains an Outperform rating on BioCryst Pharma (BCRX). The price target was lowered from $21 to $20. The move reflects a conservative adjustment to valuation expectations while retaining a bullish long-term view on the stock.
